Company news
Advicenne SA news in 2026
Advicenne SA's news releases, calls and decks from 2026, newest first.
Advicenne reports First Half financial results as of June 30, 2026, and updates on its activities
October 20, 2026
Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance
October 11, 2026
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
September 30, 2026
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
September 27, 2026
Advicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its Activities
September 17, 2026
Advicenne decides to withdraw its ADV7103 New Drug Application in the USA
August 31, 2026
Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain
July 20, 2026
Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France
July 16, 2026
Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom
July 1, 2026
Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million
June 23, 2026
Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million
June 22, 2026
Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million
June 1, 2026
Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026
May 21, 2026
Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway
May 5, 2026
Advicenne 2025 Universal Registration Document Made Available
April 24, 2026
Advicenne Reports Its 2025 Annual Financial Results
March 26, 2026
Advicenne: Official Reimbursement of Sibnayal® for the Treatment of dRTA in France
February 2, 2026
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in UAE
January 27, 2026
Advicenne: 2025 Full Year Sales
January 22, 2026
Advicenne: 2026 Financial Calendar
January 20, 2026
Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal® in the United States for the Treatment of dRTA
January 19, 2026
Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal® in European Union
January 12, 2026